Focus on gastric cancer

Cancer Cell

Volumn 5, Issue 2, 2004, Pages 121-125

  Ushijima, Toshikazu ^a   Sasako, Mitsuru ^b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; IRINOTECAN;

CANCER CHEMOTHERAPY; CANCER SUSCEPTIBILITY; DEVELOPING COUNTRY; GASTROINTESTINAL ENDOSCOPY; GENE MUTATION; HISTOLOGY; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STOMACH CARCINOMA;

EID: 1442310498     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(04)00033-9     Document Type: Review

References (44)

1. Allum W.H., Griffin S.M., Watson A., Colin-Jones D. Guidelines for the management of oesophageal and gastric cancer. Gut. 50:2002;1-23.
2. Becker K.F., Atkinson M.J., Reich U., Becker I., Nekarda H., Siewert J.R., Hofler H. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res. 54:1994;3845-3852.
3. Bonenkamp J.J., Hermans J., Sasako M., van de Velde C.J.H. For the Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N. Engl. J. Med. 340:1999;908-914.
4. Cuschieri A., Weeden S., Fielding J., Bancewicz J., Craven J., Joypaul V., Sydes M., Fayers P. Br. J. Cancer. 79:1999;1522-1530.
5. Ding Y., Le X.P., Zhang Q.X., Du P. Methylation and mutation analysis of p16 gene in gastric cancer. World J. Gastroenterol. 9:2003;423-426.
6. El-Omar E.M., Carrington M., Chow W.H., McColl K.E., Bream J.H., Young H.A., Herrera J., Lissowska J., Yuan C.C., Rothman N.et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 404:2000;398-402.
7. Fang D.C., Wang R.Q., Yang S.M., Yang J.M., Liu H.F., Peng G.Y., Xiao T.L., Luo Y.H. Mutation and methylation of hMLH1 in gastric carcinomas with microsatellite instability. World J. Gastroenterol. 9:2003;655-659.
8. Fenoglio-Preiser C., Carneiro F., Correa P., Guilford P., Lambert R., Megraud F., Munoz N., Powell S., Rugge M., Sasako M.et al. Gastric carcinoma. Hamilton S., Aaltonen L. Tumours of the digestive system. 1997;39-52 IARC Press, Lyon, France.
9. Ferlay, J., Bray, F., Pisani, P., and Parkin, D.M. (2001). GLOBOCAN 2000: Cancer Incidence, Mortality, and Prevalence Worldwide, Version 1.0, Vol. 5 (Lyon: IARC Press).
10. Fertitta A.M., Comin U., Terruzzi V., Minoli G., Zambelli A., Cannatelli G., Bodini P., Bertoli G., Negri R., Brunati S.et al. Clinical significance of gastric dysplasia. a multicenter follow-up study. Gastrointestinal Endoscopic Pathology Study Group Endoscopy. 25:1993;265-268.
11. Gotoda T., Yanagisawa A., Sasako M., Ono H., Nakanishi Y., Shimoda T., Kato Y. Incidence of lymph node metastasis from early gastric cancer. estimation with a large number of cases at two large centers Gastric Cancer. 3:2000;219-225.
12. Guilford P., Hopkins J., Harraway J., McLeod M., McLeod N., Harawira P., Taite H., Scoular R., Miller A., Reeve A.E. E-cadherin germline mutations in familial gastric cancer. Nature. 392:1998;402-405.
13. Gut M.O., Parkkila S., Vernerova Z., Rohde E., Zavada J., Hocker M., Pastorek J., Karttunen T., Gibadulinova A., Zavadova Z.et al. Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterol. 123:2002;1889-1903.
14. Hasegawa S., Furukawa Y., Li M., Satoh S., Kato T., Watanabe T., Katagiri T., Tsunoda T., Yamaoka Y., Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. 62:2002;7012-7017.
15. Judd L.M., Alderman B.M., Howlett M., Shulkes A., Dow C., Moverley J., Grail D., Jenkins B.J., Ernst M., Giraud A.S. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterol. 126:2004;196-207.
16. Kaneda A., Kaminishi M., Yanagihara K., Sugimura T., Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 62:2002;6645-6650.
17. Kang G.H., Lee S., Kim W.H., Lee H.W., Kim J.C., Rhyu M.G., Ro J.Y. Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am. J. Pathol. 160:2002;787-794.
18. Koizumi W., Tanabe S., Saigennji K., Ohtsu A., Boku N., Nagashima F., Shirao K., Matsumura Y., Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer. 89:2003;2207-2212.
19. Lee J.H., Abraham S.C., Kim H.S., Nam J.H., Choi C., Lee M.C., Park C.S., Juhng S.W., Rashid A., Hamilton S.R., Wu T.T. Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am. J. Pathol. 161:2002;611-618.
20. Lefebvre O., Chenard M.P., Masson R., Linares J., Dierich A., LeMeur M., Wendling C., Tomasetto C., Chambon P., Rio M.C. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 274:1996;259-262.
21. Li Q.L., Ito K., Sakakura C., Fukamachi H., Inoue K., Chi X.Z., Lee K.Y., Nomura S., Lee C.W., Han S.B.et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 109:2002;113-124.
22. MacDonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani J.A., Gunderson L.L., Jessup J.M., Martenson J.A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345:2001;725-730.
23. Machado J.C., Oliveira C., Carvalho R., Soares P., Berx G., Caldas C., Seruca R., Carneiro F., Sobrinho-Simoes M. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 20:2001;1525-1528.
24. Maesawa C., Tamura G., Suzuki Y., Ogasawara S., Sakata K., Kashiwaba M., Satodate R. The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. J. Pathol. 176:1995;249-258.
25. Miwa H., Go M.F., Sato N. H. pylori and gastric cancer. the Asian enigma Am. J. Gastroenterol. 97:2002;1106-1112.
26. Nakajima T. Gastric cancer treatment guidelines in Japan. Gastric Cancer. 5:2002;1-5.
27. Noda N., Sasako M., Yamaguchi N., Nakanishi Y. Ignoring small lymph nodes can be a major cause of staging error in gastric cancer. Br. J. Surg. 85:1998;831-834.
28. Oberhuber G., Stolte M. Gastric polyps. an update of their pathology and biological significance Virchows Arch. 437:2000;581-590.
29. Ono H., Kondo H., Gotoda T., Shirao K., Yamaguchi H., Saito D., Hosokawa K., Shimoda T., Yoshida S. Endoscopic mucosal resection for treatment of early gastric cancer. Gut. 48:2001;225-229.
30. Oshima A. Secondary prevention. Screening methods in high-incidence area Sugimura T., Sasako M. Gastric Cancer. 1997;199-212 Oxford University Press, Oxford.
31. Oue N., Motoshita J., Yokozaki H., Hayashi K., Tahara E., Taniyama K., Matsusaki K., Yasui W. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J. Pathol. 198:2002;55-59.
32. Palli D. Epidemiology of gastric cancer. an evaluation of available evidence J. Gastroenterol. 35(Suppl 12):2000;84-89.
33. Park W.S., Oh R.R., Park J.Y., Lee S.H., Shin M.S., Kim Y.S., Kim S.Y., Lee H.K., Kim P.J., Oh S.T.et al. Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. Cancer Res. 59:1999;4257-4260.
34. Potter, J.D., Chavez, A., Chen, J., Ferro-Luzzi, A., Hirohata, T., James, W.P.T., Kadlubar, F.F., Kavishe, F.P., Kolonel, L.N., Kono, S., et al., eds (1997). Stomach. In Food, Nutrition and the Prevention of Cancer: A global perspective (Washington, D.C.: World Cancer Research Fund/American Institute for Cancer Research), pp. 148-175.
35. Sasako M. Principles of surgical treatment for curable gastric cancer. J. Clin. Oncol. 21:2003;274s-275s.
36. Schlemper R.J., Itabashi M., Kato Y., Lewin K.J., Riddell R.H., Shimoda T., Sipponen P., Stolte M., Watanabe H., Takahashi H., Fujita R. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet. 349:1997;1725-1729.
37. Shimizu N., Inada K.I., Tsukamoto T., Nakanishi H., Ikehara Y., Yoshikawa A., Kaminishi M., Kuramoto S., Tatematsu M. New animal model of glandular stomach carcinogenesis in Mongolian gerbils infected with Helicobacter pylori and treated with a chemical carcinogen. J. Gastroenterol. 34:1999;61-66.
38. Takada K. Epstein-Barr virus and gastric carcinoma. Mol. Pathol. 53:2000;255-261.
39. Tatematsu M., Tsukamoto T., Inada K. Stem cells and gastric cancer. role of gastric and intestinal mixed intestinal metaplasia Cancer Sci. 94:2003;135-141.
40. Tsubono Y., Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer. 3:2000;9-18.
41. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345:2001;784-789.
42. Waki T., Tamura G., Tsuchiya T., Sato K., Nishizuka S., Motoyama T. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am. J. Pathol. 161:2002;399-403.
43. Xu X., Brodie S.G., Yang X., Im Y.H., Parks W.T., Chen L., Zhou Y.X., Weinstein M., Kim S.J., Deng C.X. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene. 19:2000;1868-1874.
44. Yamashita S., Wakazono K., Sugimura T., Ushijima T. Profiling and selection of genes differentially expressed in the pylorus of rat strains with different proliferative responses and stomach cancer susceptibility. Carcinogenesis. 23:2002;923-928.